Screening for Diabetes and Prediabetes

Daisy Duan; Andre P Kengne; Justin B Echouffo-Tcheugui

doi:10.1016/j.ecl.2021.05.002

Screening for Diabetes and Prediabetes

Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385. doi: 10.1016/j.ecl.2021.05.002. Epub 2021 Jul 12.

Authors

Daisy Duan¹, Andre P Kengne², Justin B Echouffo-Tcheugui³

Affiliations

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA.
² Non-Communicable Diseases Research Unit, South African Medical Research Council, Francie van Zijl Drive Parowvallei, PO Box 19070, Tygerberg, Cape Town 7505, South Africa.
³ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA; Welch Prevention Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. Electronic address: jechouf1@jhmi.edu.

Abstract

Overt type 2 diabetes mellitus (T2DM) is preceded by prediabetes and latent diabetes (lasts 9-12 years). Key dysglycemia screening tests are fasting plasma glucose and hemoglobin A_1C. Screen-detected T2DM benefits from multifactorial management of cardiovascular risk beyond glycemia. Prediabetes is best addressed by lifestyle modification, with the goal of preventing T2DM. Although there is no trial evidence of prediabetes/T2DM screening effectiveness, simulations suggest that clinic-based opportunistic screening of high-risk individuals is cost-effective. The most rigorous extant recommendations are those of the American Diabetes Association and US Preventive Services Task Force, which advise opportunistic 3-yearly screening.

Keywords: Cost-effectiveness; Diabetes; Effectiveness; Prediabetes; Screening.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / prevention & control
Glycated Hemoglobin / analysis
Humans
Mass Screening
Prediabetic State* / diagnosis
Prediabetic State* / therapy

Substances

Blood Glucose
Glycated Hemoglobin A

Abstract

Publication types

MeSH terms

Substances

Grants and funding